Merck recently announced the second cohort of the Merck Digital Sciences Studio (MDSS) in Montreal, Canada. MDSS is a collaborative digital health innovation accelerator dedicated to investing in, supporting and mentoring biopharmaceutical start-ups focused on developing cutting-edge digital technologies including artificial intelligence (AI) solutions. MDSS specifically targets innovations in the areas of preventive health, platforms for biologics research and development (R&D) and 3D translational disease models.
Congratulations to the twelve Canadian and U.S start-ups selected to be part of the second cohort! We are thrilled to see NuvoBio, an OBIO® member, among the selected companies. NuvoBio is also an alumnus of our Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence and WiHI, and presented at the OBIO® Investment Summit.